Treatment of psychic disorders and inflammation with fused isoquinolines

Abstract

New tricyclic ortho-fused heterocyclic compounds of formula ##STR1## wherein A is the group ##STR2## or the group ##STR3## in which R represents hydrogen, (C.sub.1-4)alkyl, phenyl or tolyl and R.sub.1 and may be (C.sub.1-4)alkyl, phenyl or tolyl, R.sub.2 is selected from (C.sub.1-4)alkyl, (C.sub.2-4)alkanoylmethyl, carbo(C.sub.1-3)alkoxymethyl, hydroxy(C.sub.2-4)alkyl, halo(C.sub.2-4)alkyl and a group ##STR4## wherein R.sub.3 is an alkylene group from 2 to 4 carbon atoms and R.sub.4 and R.sub.5 independently represent hydrogen or (C.sub.1-4)alkyl or, taken together with the nitrogen atom, a fully hydrogenated 5 or 6 membered heterocyclic radical which may contain a further heteroatom selected from O, N and S and be optionally substituted by a (C.sub.1-4)alkyl or phenyl group, or R.sub.2 may represent, nil the dotted lines x and y may represent nil or additional bonds; with the proviso that, when the symbol R.sub.2 linked to the oxygen atom is different from nil, x is an additional bond and y and the other symbol R.sub.2 represent nil; with the further proviso that, when the symbol R.sub.2 linked to the nitrogen atom is different from nil, y is an additional bond and x and the other symbol R.sub.2 represent nil; and salts therewith of pharmaceutically acceptable acids. The compounds possess antiinflammatory, CNS-depressent and anti-anxiety utility.

Dependencies are inferred from the claim text.